NCT02932267View on ClinicalTrials.gov

Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne

PHASE3CompletedINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

February 2, 2017

Primary Completion Date

January 10, 2018

Study Completion Date

January 10, 2018

Conditions

Acne Vulgaris

Interventions

DRUG

Adapalene 0.3% / BPO 2.5% gel

Epiduo Forte / Tactupump gel to be applied once a daily at bed time on entire face during 16 weeks

Trial Locations (3)

78759

Dermresearch, Austin

Unknown

CIDP, Phoenix

CIDP, Singapore

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Galderma R&D

INDUSTRY